Palmitoylethanolamide (PEA) Cannabinoid Research

Palmitoylethanolamide (PEA) Research Dashboard

159

Primary Studies

54

Related Studies

213

Total Studies

Clinical Studies

3

Clinical Meta-analyses

22

Double-blind Clinical Trials

35

Clinical Trials

Pre-Clinical Studies

42

Meta-analyses/Reviews

46

Animal Studies

11

Laboratory Studies

What am I missing as a non-subscriber?

To see a full dashboard with study details and filtering, go to our DEMO page.

As a subscriber, you will be able to access dashboard insights including chemotype overviews and dosing summaries for medical conditions and organ system and receptor breakdowns for cannabinoid and terpene searches. Study lists present important guidance including dosing and chemotype information with the ability to drill down to the published material. And all outputs are fully filterable, to help find just the information you need. Stay up-to-date with the science of cannabis and the endocannabinoid system with CannaKeys.

CannaKeys has 213 studies associated with Palmitoylethanolamide (PEA).

Here is a small sampling of Palmitoylethanolamide (PEA) studies by title:


Components of the Palmitoylethanolamide (PEA) Research Dashboard

  • Top medical conditions associated with Palmitoylethanolamide (PEA)
  • Proven effects in clinical trials for Palmitoylethanolamide (PEA)
  • Receptors associated with Palmitoylethanolamide (PEA)
  • Individual study details for Palmitoylethanolamide (PEA)

Ready to become a subscriber? Go to our PRICING page.

Select New Cannabinoid

Filter Cannabinoid

Members can filter by the following criteria:

  • Study Type
  • Organ Systems
  • Terpenes
  • Receptors
  • Ligands
  • Study Result
  • Year of Publication

Overview - Palmitoylethanolamide (PEA)

Description of Palmitoylethanolamide (PEA)

Palmitoylethanolamide (PEA) was identified in 1957. It is a naturally occurring compound made from fat and is produced by mammalian body's for the purpose of tissue repair. More specifically, PEA is an endogenous fatty acid amide formed, as the name implies, by combining a fatty acid with an amine (a family of organic compound containing nitrogen). The compound is one of the most common of the N-acylethanolamines (NAEs) [a family that includes anandamide (AEA) and oleoylethanolamide (OEA) a compound involved in feeling satieted].


PEA is not an endocannabinoid per se because it has no affinity (or only very weak affinity) for the classical endocannabinoid receptor sites CB1 or CB2. However, PEA may be an allosteric (indirect modulator) of CB1 and/or CB2.


PEA modulates other receptor sites that are part of the greater ECS-based environment entitled the endocannabinoidome (see the receptor site window for more information).


Foods that contain PEA include soy, egg yolk, corn, peanuts, pea and bean seeds. PEA was also discovered in human, bovine, and moose milk. Nutraceuticals containing PEA are readily available as oral supplements.

Other Names:

N-hexadecanoylethanolamide

Palmitoylethanolamide, Palmidrol, 544-31-0, N-(2-Hydroxyethyl)hexadecanamide, Palmitoyl ethanolamide


IUPAC Name: N-(2-hydroxyethyl)hexadecanamide


Molecular Formula: C18H37NO2


Source–PubChem

Palmitoylethanolamide (PEA) Properties and Effects

Only Members can view Properties and Effects information. See DEMO page.

Palmitoylethanolamide (PEA) Receptor Binding

Only Members can view Receptor Binding information. See DEMO page.

Disclaimer
Information on this site is provided for informational purposes only and is not meant to substitute for the advice provided by your own licensed physician or other medical professional. You should not use the information contained herein for diagnosing or treating a health problem or disease. If using a product, you should read carefully all product packaging. If you have or suspect that you have a medical problem, promptly contact your health care provider.

Information on this site is based on scientific studies (human, animal, or in vitro), clinical experience, or traditional usage as cited in each article. The results reported may not necessarily occur in all individuals. For many of the conditions discussed, treatment with prescription or over-the-counter medication is also available. Consult your physician, nutritionally oriented health care practitioner, and/or pharmacist for any health problem and before using any supplements or before making any changes in prescribed medications.